Novel chemotherapies more often used on- than off-label

Novel chemotherapies more often used on- than off-label
In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label, according to a study published online Feb. 19 in the Journal of Clinical Oncology.

(HealthDay)—In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label, according to a study published online Feb. 19 in the Journal of Clinical Oncology.

To examine the prevalence of off-label use of 10 commonly prescribed patent-protected anticancer drugs, Rena M. Conti, Ph.D., of the University of Chicago, and colleagues analyzed prescribing data from a pharmacy software provider maintaining a population-based cohort database including 570 medical oncologists in 122 medical oncology practices.

The researchers found that 70 percent of chemotherapy use was on-label, and 30 percent was off-label. Fourteen percent of use conformed to an off-label indication supported by the National Comprehensive Care Network (NCCN) recommendations. Ten percent of off-label use occurred at a U.S. -approved cancer site but for a stage of cancer or line of therapy that was not recommended by the NCCN. Spending on these chemotherapies amounted to $2 billion for off-label and NCCN supported uses and $2.5 billion for off-label and NCCN unsupported uses, compared with $7.3 billion for on-label uses.

"The overall proportion of off-label use that the authors identified is not high, especially when taking into account NCCN-approved indications, but the variation by drug and the associated costs are high," write the authors of an accompanying editorial. "The ultimate goal should not be zero off-label prescribing, but rather that the entire system be designed to maximize the likelihood of an optimal risk-benefit ratio for both individual patients and the system as a whole."

One author disclosed to ; a second author is an economic expert for plaintiffs in suit against the manufacturer of rituximab.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Recommended for you

Spicy treatment the answer to aggressive cancer?

date Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.